In rodent models of obesity and monkeys with diabetes, exogenous FGF21 improves glucose tolerance 1, 2, and FGF21 analogues are in clinical development for the treatment of several metabolic diseases in humans 3. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.